Elevance Health, Inc. (ELV)
As-reported financials and recent SEC filings for Elevance Health, Inc., latest fiscal period FY2025. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.
About Elevance Health, Inc.
Elevance Health, Inc. is a health insurance company serving approximately 45.2 million medical members in the United States through its affiliated health plans. The company offers a range of managed care plans and services, including medical, pharmacy, and behavioral health services, to individual, employer group, Medicaid, and Medicare markets. Its operations include health benefit plans, pharmacy services through CarelonRx, and other healthcare-related services, serving both affiliated and external customers.
Snapshot
Fundamentals are from SEC filings. P/E and market cap are derived from recent market prices, refreshed on a rolling basis (typically within the past week).
What changed at Elevance Health
- Revenue grew 12.5% to $199.1B in FY2025, faster than the 3.3% the year before.
- Operating margin is 3.6% in FY2025, -1.8 pp against 5.5% in FY2021.
- Most recent quarter Q2 FY2026: revenue $50.5B, up 1.4% from Q2 FY2025.
- Free cash flow was $3.2B in FY2025, 1.6% of revenue.
- Net income fell 5.3% to $5.7B in FY2025.
Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.
Peer comparison
Where Elevance Health’s fundamentals sit among the 424 Financials companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).
3 open-market insider buys totaling $1.4M in the last 90 days, against 3 sales totaling $826,625. For context, about 16% of companies in the universe saw any open-market insider buying in the same window. Browse insider activity →
Percentiles describe where a figure sits among sector peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.
Institutional ownership
Held by 8 of the superinvestors we track (plus 7 quant / multi-strat books), based on each investor’s most recent 13F (latest Q1 2026).
| Investor | As of | Position value | Shares | Change |
|---|---|---|---|---|
| Harris Associates (Oakmark) | Q1 2026 | $1.40B | 4.8M | Added |
| First Eagle Investment Management | Q1 2026 | $1.21B | 4.1M | Added |
| Citadel Advisorsquant | Q1 2026 | $457.3M | 1.6M | Reduced |
| Ruane Cunniff (Sequoia) | Q1 2026 | $406.3M | 1.4M | Reduced |
| Baupost Group | Q1 2026 | $373.3M | 1.3M | Added |
| Millennium Managementquant | Q1 2026 | $269.1M | 919.2K | Added |
| D. E. Shawquant | Q1 2026 | $118.9M | 406.0K | Reduced |
| Yacktman Asset Management | Q1 2026 | $97.9M | 334.3K | Added |
| AQR Capital Managementquant | Q1 2026 | $92.6M | 318.0K | Reduced |
| Point72 Asset Managementquant | Q1 2026 | $17.4M | 59.3K | New |
| Gotham Asset Management | Q1 2026 | $11.7M | 39.8K | Reduced |
| Renaissance Technologiesquant | Q1 2026 | $4.6M | 15.6K | New |
| Hound Partners | Q1 2026 | $1.2M | 3.9K | New |
| Dodge & Cox | Q1 2026 | $380,575 | 1.3K | Held |
| Two Sigma Investmentsquant | Q1 2026 | $368,865 | 1.3K | New |
From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.
Recent insider activity
Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4. Multiple insiders have bought recently (a cluster buy).
| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
2026-07-17 | BOUDREAUX GAILPresident and CEO | Buy | 2.0K | $368.25 | $753K |
2026-07-17 | PERU RAMIRO GDirector | Buy | 1.0K | $366.05 | $366K |
2026-07-17 | BOUDREAUX GAILPresident and CEO | Buy | 680 | $366.41 | $249K |
2026-06-12 filed 2026-06-15 | Penczek Ronald WCAO & Controller | Sell | 369 | $403.16 | $149K |
2026-06-11 filed 2026-06-12 | Dixon Robert L JRDirector | Sell | 151 | $401.77 | $61K |
2026-05-19 filed 2026-05-20 | Penczek Ronald WCAO & Controller | Sell | 1.5K | $403.13 | $617K |
Reported non-derivative purchases and sales (codes P/S) — which may be open-market or private; excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.
Short interest
Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 2026-07-15 | 6.0M | +0.3% | 3.52 |
| 2026-06-30 | 6.0M | -4.3% | 3.27 |
| 2026-06-15 | 6.3M | -4.9% | 3.52 |
| 2026-05-29 | 6.6M | +8.3% | 4.34 |
| 2026-05-15 | 6.1M | +18.3% | 3.68 |
| 2026-04-30 | 5.2M | +16.8% | 2.54 |
| 2026-04-15 | 4.4M | +11.3% | 2.96 |
| 2026-03-31 | 4.0M | +8.2% | 2.45 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.
Income statement (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $199.13B | $177.01B | $171.34B | $156.59B | $138.64B |
| Gross profit | — | — | — | — | — |
| Operating income | $7.20B | $7.86B | $8.50B | $8.28B | $7.56B |
| Net income | $5.66B | $5.98B | $5.99B | $5.89B | $6.16B |
| Diluted EPS | $25.21 | $25.68 | $25.22 | $24.28 | $24.95 |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full methodology.
Balance sheet (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Cash and equivalents | $9.49B | $8.29B | $6.53B | $7.39B | $4.88B |
| Current assets | $63.00B | $58.94B | $60.03B | $55.62B | $51.12B |
| Total assets | $121.49B | $116.89B | $108.93B | $102.75B | $97.46B |
| Current liabilities | $41.03B | $40.58B | $41.79B | $39.70B | $34.88B |
| Long-term debt | $30.80B | $29.22B | $23.25B | $22.35B | $21.16B |
| Total liabilities | $77.47B | $75.46B | $69.52B | $66.42B | $61.29B |
| Total equity | $44.03B | $41.43B | $39.41B | $36.33B | $36.16B |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full methodology.
Cash flow (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Operating cash flow | $4.29B | $5.81B | $8.06B | $8.40B | $8.36B |
| Capital expenditure | $1.12B | $1.26B | $1.30B | $1.15B | $1.09B |
| Free cash flow | $3.17B | $4.55B | $6.76B | $7.25B | $7.28B |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full methodology.
Quarterly trend (as reported)
| Quarter | Revenue | Revenue YoY | Net income | Diluted EPS |
|---|---|---|---|---|
| Q2 FY2026 | $50.47B | 1.4% | $1.46B | $6.71 |
| Q1 FY2026 | $50.18B | 2.6% | $1.76B | $8.00 |
| Q4 FY2025 | $49.75B | 9.5% | $547.0M | $2.47 |
| Q3 FY2025 | $50.71B | 12.4% | $1.19B | $5.32 |
| Q2 FY2025 | $49.78B | 13.4% | $1.74B | $7.72 |
| Q1 FY2025 | $48.89B | 14.8% | $2.18B | $9.61 |
| Q4 FY2024 | $45.44B | 6.6% | $418.0M | $1.81 |
| Q3 FY2024 | $45.11B | 5.3% | $1.02B | $4.36 |
Latest 8 reported quarters, from company XBRL filings on SEC EDGAR.
Company facts
Recent SEC filings
Largest Financials peers
Monitor ELV
Get an alert when Elevance Health files something material, see which superinvestors own it, and ask its filings a question with cited answers.
Monitor ELV freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.